Across the long contest between bacteria and the viruses that prey on them, a small protein from a bacteria-killing virus has been seen gripping one of the machines bacteria use to build their protective walls. Researchers at the Nara Institute of Science and Technology in Japan, led by Hidetaka Kohga, described this grip in detail in PLOS Biology in late October 2026. The finding matters because drug-resistant bacteria are spreading, and humanity needs new ways to stop them, often by learning from strategies that nature has already refined. What the team uncovered is that different viral prot
Phage Protein Locks Bacterial Lipid Transporter MurJ in Place, Pointing to New Antibiotic Targets
Locked in one position, MurJ cannot complete the cycle.
Mark
Why does it matter that three different phage proteins hit MurJ?
Mimi
Because they look nothing alike in sequence, yet all three hold MurJ in a similar outward-facing shape. The team reads that as convergent evolution on one vulnerable target.
Mark
So what does SglPP7 physically do?
Mimi
It lies along a lipid-binding groove and pushes its short C-terminal tail into a deep cavity inside MurJ. That freezes the transporter so it can't flip and carry lipid.
Luke
Careful with "convergent evolution." That's Kohga's interpretation of the structural comparison, not something the study could observe directly.
Mark
Fair. How did they get the structure?
Mimi
Cryo-electron microscopy, plus mutation experiments, cell lysis tests, and computer simulations.
Luke
And does any of this mean a new antibiotic is coming?
Mimi
No. Kohga himself calls it basic research.
Luke
Right. The source gives no drug candidate, no animal data, no timeline. What it offers is a structural foundation for drug design and engineered phage proteins.
Mark
So what should a reader watch for?
Mimi
Whether researchers use these binding modes to design molecules that mimic them.
Le Pouls
- A viral protein called SglPP7 has been caught locking a bacterial transporter, MurJ, in place, stopping the cell from building its wall.
- Drug-resistant bacteria are rising worldwide, creating urgent pressure to find antibiotic targets that existing drugs have not already exhausted.
- Using cryo-electron microscopy and mutation tests, the NAIST team mapped the viral tail lodging deep inside MurJ's cavity to freeze it in an outward-facing shape.
- Three unrelated phage proteins, SglPP7, LysM, and SglCJ3, bind MurJ in different ways yet produce the same frozen state, pointing to convergent evolution on one weak spot.
- The work remains basic research, but it gives drug designers a structural map and a path toward engineered antibacterial phage proteins.
Across the long contest between bacteria and the viruses that prey on them, a small protein from a bacteria-killing virus has been seen gripping one of the machines bacteria use to build their protective walls. Researchers at the Nara Institute of Science and Technology in Japan, led by Hidetaka Kohga, described this grip in detail in PLOS Biology in late October 2026. The finding matters because drug-resistant bacteria are spreading, and humanity needs new ways to stop them, often by learning from strategies that nature has already refined. What the team uncovered is that different viral proteins, built from quite different materials, arrive at the same point of attack, suggesting that the target itself has been repeatedly discovered as vulnerable.
A team at the Nara Institute of Science and Technology in Japan has mapped, at near-atomic detail, how a small protein from a bacteria-killing virus jams a machine bacteria need to build their cell walls. The study, published in PLOS Biology on October 27, 2026, was led by Assistant Professor Hidetaka Kohga.
The urgency comes from drug-resistant bacteria, which are becoming more common worldwide. Treating them will require new ways to kill bacteria, and that starts with finding essential processes future antibiotics could target. Bacteriophages, viruses that infect bacteria, have become one place to look, since some inject proteins that shut down key bacterial functions.
One such target is MurJ, a bacterial protein that carries lipids needed for cell wall construction. Several phage proteins already known to block MurJ share little amino acid sequence in common, which raised a puzzle: how can such different molecules stop the same machine, and do they use the same strategy?
The team focused on SglPP7. Using cryo-electron microscopy, mutation experiments, bacterial lysis tests, and computer simulations, they found the viral protein lying along a lipid-binding groove in MurJ, with its short tail buried in a deep internal cavity. That grip holds the transporter in an outward-facing shape. MurJ must flip between shapes to move lipids across the membrane, and once frozen, it cannot finish the cycle.
Comparing SglPP7 with LysM and SglCJ3 revealed that all three hold MurJ in a similar conformation, though each binds in its own way. Kohga suggested this reflects convergent evolution toward a shared target.
The hope is that these details will help design new drugs and engineered phage proteins with targeted antibacterial power. Kohga cautioned that the study is still basic research. For now, the next step is to understand more fully how these natural antibacterial mechanisms work.
A team at the Nara Institute of Science and Technology in Japan has worked out, at near-atomic detail, how a small protein made by a bacteria-killing virus jams one of the machines bacteria need to build their walls. The study, published in PLOS Biology on October 27, 2026, was led by Assistant Professor Hidetaka Kohga.
The backdrop is familiar: drug-resistant bacteria are becoming more common worldwide, and treating them will require new ways of killing bacteria. That in turn means identifying essential cellular processes that future antibiotics could target. One place researchers have looked is a class of viruses called bacteriophages, or phages, which infect bacteria and hijack their machinery to replicate. Some phages inject small proteins that switch off specific bacterial processes, and the cell ultimately dies.
One target of those proteins is MurJ, a bacterial protein that moves lipids needed for building the cell wall. Several phage proteins that inhibit MurJ are already known, but their amino acid sequences differ considerably. That raised the question the NAIST team set out to answer: how can such different proteins block the same essential target, and do they all use the same molecular strategy?
The team focused on a phage protein called SglPP7. They used cryo-electron microscopy, which reveals the structures of biological molecules at near-atomic resolution, to determine the structure of MurJ bound to SglPP7. They also ran experiments with targeted protein mutations and bacterial cell lysis, along with computer simulations, to test how the interaction changes MurJ's behavior. Co-authors were Kaito Hosoda, Sixian Wu, Hiroyuki Tanaka, Hideki Shigematsu, Ryoji Miyazaki, Min Fey Chek, and Tomoya Tsukazaki, all at NAIST.
The structure showed SglPP7 lying along a lipid-binding groove in MurJ, with its short C-terminal tail inserted into a deep internal cavity. That grip holds MurJ in an outward-facing conformation. MurJ normally has to flip back and forth between shapes to carry lipid across the membrane, and locked in one position it cannot complete the cycle.
The researchers then compared SglPP7 with two other known phage proteins that act on MurJ, LysM and SglCJ3. All three stabilize a similar conformation of MurJ, even though each binds the transporter in a different way. Kohga said the findings suggest convergent evolution toward a common target through diverse inhibitory mechanisms.
The practical hope is that understanding these interactions could help researchers design new drugs and engineer artificial phage proteins with targeted antibacterial activity. Kohga said the study provides a foundation for drug discovery aimed at this transporter, but he stressed that it is still basic research. The work may eventually contribute to new antibacterial agents against drug-resistant bacteria; for now, the next step is further study of the antibacterial mechanisms that evolved naturally.
Citations marquantes
These findings suggest convergent evolution toward a common target through diverse inhibitory mechanisms.— Dr. Hidetaka Kohga, NAIST
The study provides a foundation for drug discovery targeting this transporter, though it is still basic research.— Dr. Hidetaka Kohga, NAIST
Envie de l'histoire complète ?
Lire l'original sur News-Medical ↗